40515-98-8

Upstream product

• 59825-50-2 1-bromo-2-<(2,6-dimethoxy)phenoxy>ethane 
• 91-10-1 1,3-dimethoxy-2-hydroxy-benzene 
• 87780-28-7 N-[2-(2,6-dimethoxy-phenoxy)-ethyl]-phthalimide 

Downstream Products

• 116635-86-0 2-(2,6-dimethoxyphenoxy)-N-(1H-indol-2-ylmethylene)ethanamine 
• 130905-05-4 (2S,3R)-3-{[2-(2,6-Dimethoxy-phenoxy)-ethylamino]-methyl}-2-phenyl-chroman-4-one 
• 96649-40-0 N²-[2-(2,6-Dimethoxy-phenoxy)-ethyl]-6,7-dimethoxy-quinazoline-2,4-diamine 
• 95110-15-9 2-methoxyphenoxymethylcarboxyamide 
• 87780-29-8 di<2-(2,6-dimethoxyphenoxy)ethyl>amine oxalate 
• 130905-06-5 3-Phenyl-2,3-dihydro-benzo[1,4]dioxine-2-carboxylic acid [2-(2,6-dimethoxy-phenoxy)-ethyl]-amide 
• 85084-42-0 N-[2-(2,6-Dimethoxy-phenoxy)-ethyl]-2,3-dihydro-benzo[1,4]dioxine-2-carboxamidine; hydrochloride 
• 95110-14-8 2,6-dimethoxyphenoxymethylcarboxy amide 
• 92642-96-1 2,3-Dihydro-benzo[1,4]oxathiine-2-carboxylic acid [2-(2,6-dimethoxy-phenoxy)-ethyl]-amide 
• 92642-96-1 (R)-2,3-Dihydro-benzo[1,4]oxathiine-2-carboxylic acid [2-(2,6-dimethoxy-phenoxy)-ethyl]-amide 
• 92642-96-1 (S)-2,3-Dihydro-benzo[1,4]oxathiine-2-carboxylic acid [2-(2,6-dimethoxy-phenoxy)-ethyl]-amide 

Relevant academic research and scientific papers

An integrative study to identify novel scaffolds for sphingosine kinase 1 inhibitors

Sphingosine kinase 1 (SphK1), the enzyme that produces the bioactive sphingolipid metabolite, sphingosine-1-phosphate, is a promising new molecular target for therapeutic intervention in cancer and inflammatory diseases. In view of its importance, the main objective of this work was to find new and more potent inhibitors for this enzyme possessing different structural scaffolds than those of the known inhibitors. Our theoretical and experimental study has allowed us to identify two new structural scaffolds (three new compounds), which could be used as starting structures for the design and then the development of new inhibitors of SphK1. Our study was carried out in different steps: virtual screening, synthesis, bioassays and molecular modelling. From our results, we propose a new dihydrobenzo[b]pyrimido[5,4-f]azepine and two alkyl{3-/4-[1-hydroxy-2-(4-arylpiperazin-1-yl)ethyl]phenyl}carbamates as initial structures for the development of new inhibitors. In addition, our molecular modelling study using QTAIM calculations, allowed us to describe in detail the molecular interactions that stabilize the different Ligand-Receptor complexes. Such analyses indicate that the cationic head of the different compounds must be refined in order to obtain an increase in the binding affinity of these ligands.

Method for synthesizing asymmetric C-O coupled compound and application of asymmetric C-O coupled compound

The invention discloses a method for synthesizing an asymmetric C-O coupled compound and application of the asymmetric C-O coupled compound and belongs to the technical field of chemical synthesis. According to the method, a compound represented by a form

Synthesis and pharmacological activity of a new series of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol analogs

β-Adrenergic receptor antagonists are important therapeutics for the treatment of cardiovascular disorders. In the group of β-blockers, much attention is being paid to the third-generation drugs that possess important ancillary properties besides inhibiting β-adrenoceptors. Vasodilating activity of these drugs is produced through different mechanisms, such as nitric oxide (NO) release, β2-agonistic action, α1-blockade, antioxidant action, and Ca2t entry blockade. Here, a study on evaluation of the cardiovascular activity of five new compounds is presented. Compound 3a is a methyl and four of the tested compounds (3b–e) are dimethoxy derivatives of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)-ethylamino)propan-2-ol. The obtained results confirmed that the methyl and dimethoxy derivatives of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol and their enantiomers possess α1- and β1-adrenolytic activities and that the antiarrhythmic and hypotensive effects of the tested compounds are related to their adrenolytic properties.

Molecular properties of the WB4101 enantiomers and of its chiral methyl derivatives for α1-adrenoceptor recognition

The optical isomers of the well known α1-antagonist WB4101 and of its derivatives with a methyl group in the oxyethyl moiety were prepared for the evaluation of their α-adrenoceptors binding affinity. By means of a detailed computational analysis, the present work shows that the introduction of a methyl group affects the behaviour of WB4101 in different ways. A limitation of the conformational freedom in certain regions of the torsional subspace of the potential energy function, differences in the reactivity of the protonated species towards a model proton acceptor and the quality of the superposition with the rigid template for α1 antagonists, corynanthine, are examined and discussed in order to select a candidate bioactive form and possible features which act as modulators of the recognition process at the α1-adrenoceptors.

Some potential α-adrenoreceptor blocking 1,4-benzodioxanes and 2,6-dimethoxyphenoxyethylamines

The synthesis and α-adrenoreceptor blocking activity of a series of 1,4-benzodioxanes and 2,6-dimethoxyphenoxyethylamines has been described. A number of analogues exhibited α-blockade, but none approached the potency of the benzodioxane WB 4101. Some mem